<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types
Background Image

CrownSyn™ Drug combination Analysis Service

Leading the Way in Drug Synergy Research in Oncology

In the intricate landscape of oncology, our unyielding pursuit for innovative solutions against cancer has spotlighted a promising area: drug synergy. This concept has rapidly come to the forefront and is now a central and pivotal focus in cutting-edge cancer research.

Why Combine Drugs?

Cancer is not a singular disease but a myriad of ailments with complex gene and molecular interactions. While a single drug might target one specific pathway, cancer can adapt by leveraging other untargeted pathways, leading to drug resistance. This brings drug combinations into the limelight, which can offer multiple advantages:

  1. Reduce Resistance: Attacking cancer from various angles reduces the chance for the disease to develop treatment resistance.

  2. Increase Potency: Drugs can enhance each other's effects, resulting in a stronger suppression of the tumor.

  3. Minimize Side Effects: Employing lower doses of each drug can potentially diminish adverse reactions while still retaining treatment efficacy.

Assessing Drug Synergy in In Vitro Studies

The allure of drug combinations is undeniable in the realm of medical research. Discerning which combinations truly synergize, however, has posed significant challenges. Traditionally, the synergy between drugs was explored using advanced statistical methods in standard cell lines. These in vitro studies are invaluable, providing preliminary insights into potential drug interactions before advancing to animal or human trials.

Recently, the advent of organoid technology has revolutionized these studies. Organoids offer a more complex and human-relevant model. By assessing drug combinations in these organoids, scientists can observe not just the interactions at a cellular level, but also how these drugs affect a more tissue-like structure. Incorporating organoids into drug synergy studies allows for a deeper understanding of drug interactions, potential toxicities, and effectiveness. The utilization of organoids in assessing drug combinations underscores a significant leap in in vitro studies, promising more reliable and human-relevant data in the pursuit of effective therapeutic strategies.

Did you know?

Drug Combination can also be evaluated on organoid models. This innovative approach allows for a more comprehensive understanding of how drugs interact within a more accurate representation of human tissue.

Click to explore how organoids are transforming drug combination studies.

Learn More

Breakthroughs and Challenges in In Vivo Models

Translating these findings to animal models has its own set of hurdles. Previous in vivo drug synergy studies often lacked rigorous statistical tools, which could lead to false positives. The ramifications of such inaccuracies are grave: combinations that seem promising in animal models could flounder in clinical trials.

Our publication in Cancer Research Communications heralds a transformative approach. We've introduced a method that meticulously and reliably detects drug synergy in various models. This technique is unprecedented, analyzing synergy directly from tumor volume data without making undue assumptions about tumor growth dynamics. With the advent of the invivoSyn framework, we're equipped with a potent tool to scrutinize drug synergy in vivo. Its insights, grounded in robust statistical methodologies, will play an instrumental role in shaping the trajectory of combination therapy studies. As drug synergy continues to occupy a pivotal position in therapeutic stratagems, especially in oncology, tools like invivoSyn will be indispensable. We're eager to further expand its capabilities, ensuring it aligns with an even broader array of datasets.

CrownSyn Service

Delving deeper into this promising arena, Crown Bioscience offers CrownSyn – a dedicated service for both in vitro and in vivo studies.

With the CrownSyn service, seamlessly evaluate and quantify the effects of two-drug combinations—be it synergistic, antagonistic, or additive—in both in vitro and in vivo assays. You can use data from your existing assays, or collaborate with our experts to design a study. Benefit from our diverse range of assay options and our rigorously validated in vitro and in vivo models.

Flexible Functionality

Adapting to various experimental designs, including fixed ratio and matrix designs.

Quantitative Data Visualization

From dose-response curves to 3D response surface plots, our platform paints a comprehensive picture of drug interactions.

Robust Data Analysis

Tried and tested in numerous studies, CrownSyn guarantees data integrity and reliability.

Related Resources

SynAI: An AI-driven Cancer Drugs Synergism Prediction Platform Image
Download Now
Statistical Assessment of Drug Synergy from <i>In Vivo</I> Combination Studies Using Mouse Tumor Models Image
Download Now
Revolutionizing Cancer Drug Combination Discovery with AI: Introducing SynAI Image
Read now

Discuss Your CrownSyn Project

Tell us more about your project!

Get In Touch